Executive Vice President, Head of Research & Development, Sanofi
Appears in 1 story
Leading Sanofi's response to FDA rejection
The FDA just rejected Sanofi's tolebrutinib for progressive multiple sclerosis on December 28, 2025—a crushing blow for a drug that had won Breakthrough Therapy status and became the first BTK inhibitor approved anywhere in the world. Meanwhile, Roche's rival drug fenebrutinib is racing toward approval after stunning Phase 3 victories, and Merck's evobrutinib crashed out entirely. Three pharma giants bet billions that brain-penetrating BTK inhibitors could finally slow the relentless neurodegeneration that leaves MS patients in wheelchairs. Only one looks likely to reach the finish line first.
Updated Dec 28, 2025
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
